^
    1m
    A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML. (PubMed, Blood Adv)
    In conclusion, ceralasertib 160mg BID d1-7 and 15-21 was established as monotherapy dosing with a response rate of 30% in patients with R/R MDS and CMML. NCT03770429.
    P1/2 data • Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    RUNX1 mutation
    |
    ceralasertib (AZD6738)
    2ms
    Common DNA Damage Response Factors Required for Cellular Resistance to Inhibitors for the Ataxia Telangiectasia and Rad3-Related Checkpoint Kinase in Hematopoietic Cells. (PubMed, Biomolecules)
    We then compared cellular sensitivity patterns of the known ATR inhibitor, VE-821, and the potential ATR inhibitors, SPK67 and SPK98, in 24 types of mutants deficient in genome maintenance systems and found that RAD17/-, FEN1-/-, and POLB-/- cells exhibited hypersensitivity to all these drugs...These results suggest that, although ATR inhibition causes DNA damage, impaired checkpoint function suppresses the appropriate activation of DNA damage signaling pathways, thereby leading to cell death. This study is the first to demonstrate the importance of Rad17, Fen1, and Polymerase β in cellular tolerance to ATR inhibition in hematopoietic cells.
    Journal
    |
    ATR (Ataxia telangiectasia and Rad3-related protein) • CHEK1 (Checkpoint kinase 1) • POLG2 (DNA Polymerase Gamma 2, Accessory Subunit) • FEN1 (Flap Structure-Specific Endonuclease 1) • RAD17 (RAD17 Checkpoint Clamp Loader Component)
    |
    VE-821
    2ms
    Replication origin firing capacity indicates ATR inhibitor sensitivity. (PubMed, Nat Commun)
    High expression of replication initiation factors predicts ATRi sensitivity across cell lines from multiple cancer types and acute myeloid leukemia patient samples. This study reveals a contribution of lethal origin firing capacity to ATR sensitivity, providing key steps towards developing a multimodal clinically applicable biomarker.
    Journal
    |
    CDC45 (Cell Division Cycle 45) • CDC7 (Cell Division Cycle 7)
    2ms
    NRG-GY031: Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (clinicaltrials.gov)
    P1, N=65, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Jun 2027 | Trial primary completion date: Apr 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability) • ARID1A (AT-rich interaction domain 1A)
    |
    MSI-H/dMMR
    |
    ZEN-3694 • tuvusertib (M1774)
    2ms
    Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (clinicaltrials.gov)
    P1, N=74, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    cisplatin • gemcitabine • elimusertib (BAY 1895344)
    2ms
    Transient ATR inhibition following ionizing radiation enhances immune-mediated antitumor response and survival. (PubMed, bioRxiv)
    In vivo and in vitro studies have shown enhanced tumor cell radiosensitivity with the ATRi ceralasertib, elimusertib, and berzosertib, however, the potentiating effect of ATRi on ionizing radiation (IR) through immune-based mechanisms has only been studied with ceralasertib. ATRi elicited differential inflammatory gene induction and dose-dependent unique cytotoxicity profiles in vitro . The immune mediated antitumor effect of ATRi combined with radiation is dose and schedule dependent, and while likely a class effect, may differ between ATRi compounds.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    berzosertib (M6620) • ceralasertib (AZD6738) • elimusertib (BAY 1895344)
    2ms
    Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=39, Recruiting, National Cancer Institute (NCI) | Initiation date: Jun 2026 --> Feb 2027 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date • Tumor mutational burden
    |
    camonsertib (RP-3500)
    2ms
    Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) (clinicaltrials.gov)
    P2, N=63, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial primary completion date: Sep 2025 --> Jun 2026
    Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    BRCA1 mutation • HRD
    |
    Zejula (niraparib) • tuvusertib (M1774) • lartesertib (M4076)
    2ms
    Integrative analysis of lncRNAs associated with disulfidptosis-related genes for prognostic risk evaluation and tumor immune microenvironment assessment in laryngeal squamous cell carcinoma. (PubMed, Hum Cell)
    Exploratory in silico drug-response analyses identified differential predicted responses to entinostat, linsitinib, and VE-822 according to risk status and DUBR expression. This internally validated signature may support exploratory prognostic risk stratification of LSCC within the analyzed TCGA-derived cohort and may highlight DUBR as a candidate molecule for further biological investigation. Further validation in independent external cohorts and dedicated disulfidptosis functional assays is required before these findings can be considered generalizable.
    Journal
    |
    TLN1 (Talin 1) • METTL3 (Methyltransferase Like 3)
    |
    berzosertib (M6620) • Jingzhuda (entinostat) • linsitinib (ASP7487)
    2ms
    ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Washington University School of Medicine
    New P1 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    decitabine • ATRN-119
    2ms
    Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study. (PubMed, Cancer Res Commun)
    Ceralasertib monotherapy was tolerated; however, responses were limited. Alternative patient selection and combination treatments are being explored.
    P2a data • Journal
    |
    ATM (ATM serine/threonine kinase)
    |
    ceralasertib (AZD6738)
    3ms
    Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Apr 2026 --> Jan 2027 | Trial primary completion date: Apr 2026 --> Jan 2027
    Trial completion date • Trial primary completion date • Checkpoint inhibition • IO biomarker
    |
    ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    |
    Bavencio (avelumab) • tuvusertib (M1774) • lartesertib (M4076)